secwatch.observer — SEC 8-K summary
======================================

Issuer:     Passage BIO, Inc. (PASG)
CIK:        0001787297
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001558370-24-008054
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Passage Bio Q1 net loss $16.7M, cash $104.5M; PBFT02 shows sustained CSF PGRN in 2 patients
--------------------------------------------------------------------------------

- Net loss of $16.7M ($0.30/shr) vs $34.3M a year ago; cash $104.5M, runway through Q4 2025.
- Dose 1 PBFT02 elevated CSF progranulin (21.7–27.3 ng/mL) at 6 months in 2 FTD-GRN patients.
- Completed dosing Cohort 1 (n=5) in upliFT-D trial; 6-month safety/biomarker data due 2H 2024.
- Plan to initiate Cohort 2 dosing in 1H 2024; FDA feedback sought for FTD-C9orf72 indication.
- Raised $8.7M net under ATM facility in Q1 2024; R&D expenses $11.5M, G&A $6.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024008054/0001558370-24-008054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787297/000155837024008054/pasg-20240514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-008054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer